Investment Rating - The report assigns a "Buy" rating for Far East Horizon (3360.HK) with a target price of HKD 7.4, indicating a potential upside from the current price of HKD 6.43 [4]. Core Insights - Far East Horizon is a comprehensive group straddling financial and industrial sectors, backed by state-owned enterprises, with a stable shareholding structure and experienced management [1][12]. - The company has diversified its operations from leasing to a comprehensive service provider, with main business segments including financial and consulting services, equipment operation, and hospital operation, contributing 57.5%, 30.68%, and 10.84% to revenue in 2024, respectively [1][13]. - The company has maintained a stable dividend payout ratio of around 30% since its listing in 2011, with a notable increase to 56.2% in 2024, and a dividend yield of 9.7%, surpassing the industry average of 6.2% [3][4]. Summary by Sections Company Overview - Far East Horizon operates as an independent business leasing company and is the largest in China, serving over 30,000 clients with a cumulative funding scale of approximately CNY 1 trillion [13]. - The company has a stable shareholding structure with major shareholders including Sinochem Capital Investment Management (21.29%) and others, ensuring strategic consistency [1][12]. Financial Performance - In 2024, the company reported total assets of CNY 360.39 billion and equity of CNY 48.99 billion, with a slight increase in total assets by 2.5% year-on-year [14]. - Revenue from financial and consulting services decreased by 7.1% to CNY 217.06 billion, while equipment operation revenue increased by 20.5% to CNY 115.81 billion [24]. - The overall operating income for 2024 was CNY 400.41 billion, reflecting a decline of 1.43% compared to the previous year [30]. Business Segments - The financial and consulting services segment remains the largest revenue contributor, although its share has decreased, while the equipment operation segment has shown significant growth [24]. - The hospital operation segment reported a revenue of CNY 40.93 billion, a decrease of 3.4% year-on-year, but with a gross profit increase of 7.5% to CNY 8.09 billion [3][14]. Future Projections - Revenue projections for 2025 to 2027 are CNY 385.4 billion, CNY 398.2 billion, and CNY 417.9 billion, with expected growth rates of 2.1%, 3.3%, and 5.0%, respectively [3]. - The company anticipates achieving net profits of CNY 40.1 billion, CNY 42.3 billion, and CNY 44.8 billion over the same period, with corresponding EPS of CNY 0.87, CNY 0.92, and CNY 0.97 [3].

2025 年 3 月 18 日 公司研究 24 年归母净利润同比增长 5.5%，新签合同额再创新高 ——中石化炼化工程（2386.HK）2024 年报点评 买入（维持） 当前价：5.63 港元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：蔡嘉豪 执业证书编号：S0930523070003 021-52523800 caijiahao@ebscn.com 分析师：王礼沫 执业证书编号：S0930524040002 010-56513142 wanglimo@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 43.98 | | 总市值(亿港元)： | 247.60 | | 一年最低/最高(港元)： | 4.28/6.87 | | 近 3 月换手率： | 46.1 | 股价相对走势 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | -14.7 | -35.3 | -3.7 | | 绝对 | -8. ...

2025 年 3 月 18 日 公司研究 24 年归母净利润同比增长 5.5%，新签合同额再创新高 ——中石化炼化工程（2386.HK）2024 年报点评 买入（维持） 当前价：5.63 港元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：蔡嘉豪 执业证书编号：S0930523070003 021-52523800 caijiahao@ebscn.com 分析师：王礼沫 执业证书编号：S0930524040002 010-56513142 wanglimo@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 43.98 | | 总市值(亿港元)： | 247.60 | | 一年最低/最高(港元)： | 4.28/6.87 | | 近 3 月换手率： | 46.1 | 股价相对走势 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | -14.7 | -35.3 | -3.7 | | 绝对 | -8. ...

Investment Rating - The report maintains a "Buy" rating for Ping An Good Doctor (01833.HK) [1][6] Core Views - The company achieved its first profit turnaround in 2024, with total revenue reaching 4.808 billion yuan, a year-on-year increase of 2.59%. The net profit was 81 million yuan, marking a successful return to profitability [1][6] - The growth was driven by the collaboration between the F-end (individual customers) and B-end (enterprise customers) businesses, with F-end revenue at 2.417 billion yuan (+9.6%) and B-end revenue at 1.432 billion yuan (+32.7%) [1][6] - The company is expanding its presence in the medical AI sector, with the launch of the digital avatar "Ping An Xin Yi" and improvements in AI-assisted diagnosis accuracy [1][6] - A special dividend was approved, with a payout of 9.7 HKD per share, totaling approximately 10.85 billion HKD, enhancing long-term value [1][6] Financial Summary - Total revenue for 2024 is projected at 4.808 billion yuan, with expected growth rates of 11.7%, 10.3%, and 10.1% for 2025-2027 [3][6] - Net profit is forecasted to grow significantly, with estimates of 245 million yuan in 2025 and 342 million yuan in 2027, reflecting growth rates of 200.7% and 10.7% respectively [3][6] - The target price is set at 10.78 HKD, with the current price at 7.61 HKD, indicating potential upside [3][6]

Investment Rating - The report maintains an "Outperform" rating for China Hongqiao (01378) [2][6] Core Views - The company has demonstrated robust performance with a significant increase in net profit by 95.2% year-on-year for 2024, driven by rising sales and decreasing raw material costs [6][7] - The company is positioned well in the market with a high dividend yield of approximately 11%, reflecting its strong long-term investment value [6][7] - The supply-demand dynamics for electrolytic aluminum are favorable, with limited supply growth and increasing demand from sectors like new energy vehicles [6][7] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 133,624 million RMB - 2024: 156,169 million RMB - 2025E: 153,099 million RMB - 2026E: 158,004 million RMB - 2027E: 158,736 million RMB - Net profit forecasts are: - 2023: 11,461 million RMB - 2024: 22,372 million RMB - 2025E: 21,869 million RMB - 2026E: 24,585 million RMB - 2027E: 25,293 million RMB - The company’s earnings per share (EPS) are projected to be: - 2023: 1.21 RMB - 2024: 2.36 RMB - 2025E: 2.31 RMB - 2026E: 2.60 RMB - 2027E: 2.67 RMB [6][7] Key Events - The company announced a final dividend for 2024, with a total payout of 161 HKD cents per share, indicating a strong commitment to returning value to shareholders [6][7] - The report highlights a decrease in coal prices, which has positively impacted the company's cost structure, leading to improved profitability [6][7]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook based on its competitive advantages and market positioning [4][47]. Core Insights - The company is a leading brand in the ready-to-drink beverage sector, benefiting from multiple competitive advantages that facilitate rapid growth [4][7]. - The Chinese ready-to-drink beverage market is experiencing significant growth, with a projected CAGR of 18% from 2023 to 2028, indicating substantial future potential [16][18]. - The company has established itself as the largest player in the domestic market, with a market share that has consistently increased over recent years [9][31]. Summary by Sections Financial Performance - The company’s revenue is projected to grow from 20,302 million RMB in 2023 to 34,344 million RMB by 2026, with year-on-year growth rates of 49.55%, 25.20%, 18.98%, and 13.56% respectively [5][47]. - The net profit attributable to shareholders is expected to reach 55.98 billion RMB by 2026, reflecting a growth of 42.58% in 2024, followed by 14.45% and 9.35% in subsequent years [5][47]. Competitive Advantages - The company maintains a high-quality and affordable product strategy, with an average price around 6 RMB, catering to a broad customer base [6][28]. - As of Q3 2024, the company has a total of 45,302 stores, making it the largest ready-to-drink beverage company globally by store count [6][35]. - The company emphasizes supply chain efficiency, achieving a high self-production ratio and maintaining lower procurement costs compared to competitors [6][37]. - The "Snow King" IP has significantly enhanced the company's marketing capabilities, contributing to a strong brand presence and customer engagement [6][38]. Market Outlook - The ready-to-drink beverage market in China is expected to grow from 5,175 billion RMB in 2023 to 11,634 billion RMB by 2028, with a market share increase from 36.3% to 49.2% of the beverage market [20][22]. - The company is well-positioned to capitalize on the growing demand for affordable ready-to-drink beverages, particularly in lower-tier cities where market growth is robust [20][28].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a revenue of 10.074 billion yuan for 2024, representing a year-on-year increase of 19.6%, and a net profit of 1.149 billion yuan, also up by 19.5% year-on-year [8] - The company is focusing on expanding its "super product stores" and aims to open 100 new stores in 2025, which is expected to contribute to growth [8] - The company maintains a strong position in the domestic sportswear market, driven by its adult and children's apparel segments, as well as e-commerce initiatives [8] Financial Performance Summary - Total revenue for 2023 was 8.423 billion yuan, with a projected increase to 10.074 billion yuan in 2024, and further growth expected in subsequent years [1] - The net profit for 2023 was 961.43 million yuan, with projections of 1.149 billion yuan for 2024, and continued growth anticipated through 2027 [1] - The earnings per share (EPS) is expected to rise from 0.46 yuan in 2023 to 0.56 yuan in 2024, with a steady increase projected through 2027 [1] Revenue Breakdown - Adult apparel revenue grew by 16.5% year-on-year, while children's apparel revenue increased by 18.0% year-on-year, contributing to 73% and 29% of total revenue respectively [8] - The revenue from adult footwear reached 4.29 billion yuan, up 22.1% year-on-year, while children's footwear revenue was 1.1 billion yuan, up 17.5% year-on-year [8] Online and Offline Sales Performance - Online sales increased by 12.2% year-on-year, while offline sales grew by 20.5% [8] - The company emphasizes differentiated products online, achieving a 99% increase in sales during the "618" shopping festival [8] Profitability and Cash Flow - The gross margin improved by 0.43 percentage points to 41.53% in 2024, with net profit margin remaining stable at 11.4% [8] - Operating cash flow for 2024 was reported at 69.81 million yuan, a decrease of 83% year-on-year due to increased procurement and supplier payments [8]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company reported a revenue of $594 million for 2024, reflecting a year-over-year increase of 6.1%, and a significant net profit of approximately $2.96 billion, primarily due to the deconsolidation of its cell therapy business, which contributed $3.2 billion in earnings [1] - The life sciences segment achieved a revenue of $455 million in 2024, growing by 10.2% year-over-year, with an adjusted operating profit of $90 million, up 15.5% [2] - The CDMO business saw a revenue decline of 13.2% to $95 million in 2024, with an adjusted operating loss of $43 million, attributed to unfavorable market conditions and increased competition [3] - The synthetic biology segment experienced a revenue increase of 24.6% to $54 million, with adjusted operating profit remaining stable at approximately $2.1 million [3] - The company expects a revenue growth of 15%-20% in the CDMO business for 2025, driven by new project acquisitions and anticipated upfront payments from partners [3] Summary by Sections Financial Performance - The company achieved a total revenue of $594 million in 2024, with a significant turnaround in net profit to $2.96 billion from a loss of $95 million in 2023 [5] - The projected net profits for 2025 and 2026 are $248 million and $235 million, respectively, with an expected EPS of $0.12 and $0.11 [4][5] Business Segments - Life Sciences: Revenue of $455 million in 2024, with a focus on innovation and automation leading to improved operational efficiency [2] - CDMO: Revenue of $95 million in 2024, with a forecasted recovery in 2025 due to new project acquisitions [3] - Synthetic Biology: Revenue growth of 24.6% in 2024, driven by expanding customer base and market penetration [3] Valuation Metrics - The company’s current valuation is considered low, with projected PE ratios of 14, 15, and 7 for 2025, 2026, and 2027, respectively [4]

证券研究报告·海外公司点评·纺织及服饰(HS) 361 度（01361.HK） 2024 年业绩点评：营收破百亿，期待超品店 表现 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 8423 | 10074 | 11377 | 12653 | 13990 | | 同比(%) | 20.24 | 19.59 | 12.94 | 11.22 | 10.57 | | 归母净利润（百万元） | 961.43 | 1,148.62 | 1,304.14 | 1,457.57 | 1,616.25 | | 同比(%) | 28.68 | 19.47 | 13.54 | 11.76 | 10.89 | | EPS-最新摊薄（元/股） | 0.46 | 0.56 | 0.63 | 0.70 | 0.78 | | P/E（现价&最新摊薄） | 9.24 | 7.73 | 6.81 | 6.09 | 5.49 | [Table_Tag ...

市场表现 [Table_QuoteInfo] 恒生指数对比 1M 2M 3M 绝对涨幅（%） -10.62 -0.44 -33.19 相对涨幅（%） -20.40 -26.33 -53.06 资料来源：海通证券研究所 收入增速修复，短期费用投放影响利润率 [Table_Summary] 投资要点： 风险提示：原材料价格上涨，新品推广不及预期，费用投放超预期。 [Table_MainInfo] 公司研究/造纸轻工/轻工制造 证券研究报告 蓝月亮集团（6993）公司研究报告 2025 年 03 月 17 日 [Table_InvestInfo] 投资评级 优于大市 首次 覆盖 股票数据 | 0[3Table_StockInfo 月 17 日收盘价 ] | 3.11 港元 | | --- | --- | | 52 周股价波动 | 1.73~4.44 港元 | | 总股本/流通港股 | 58.63 亿/58.63 亿 | | 总市值/流通市值 | 182 亿/182 亿港元 | | 相关研究 | | 主要财务数据及预测 | [Table_FinanceInfo] | 2022 | 2023 | 2024E | 202 ...